127984-74-1

Basic information

• Product Name: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide
• Synonyms: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;Somatulina;3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate
• CAS NO: 127984-74-1
• Molecular Formula: C54H69N11O10S2
• Molecular Weight: 0
• Product Categories: Amino Acids & Derivatives, Pharmaceuticals, Intermediates & Derivatives
• Mol File: 127984-74-1.mol

Chemical Properties

• Appearance: white to off-white/
• Storage Temp.: ?20°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide(127984-74-1)
• EPA Substance Registry System: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide(127984-74-1)

Safety Data

• Hazard Codes: Xn
• Statements: 63
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 127984-74-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide is used as a potential therapeutic agent for various diseases due to its unique chemical properties and structural features. Its amine and carboxylic acid functional groups allow for interactions with biopolymers and macromolecules, making it a promising candidate for drug development.
Used in Chemical Research:
10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide can also be used as a research tool in the field of organic chemistry, particularly in the study of complex molecular structures and their properties. Its unique features can provide insights into the design and synthesis of new compounds with potential applications in various industries.
Used in Material Science:
The structural features of 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide may also make it a candidate for the development of new materials with specific properties, such as improved stability, reactivity, or selectivity.

Originator

Beaufour-Ipsen (France)

Biochem/physiol Actions

Lanreotide acetate is a somatostatin analog, a selective agonist for the SRIF-1 sst2 subtype of somatostatin receptor with a binding affinity of 0.8 nM for sst2 compared to 5.2 nM for sst5, 100 nM for sst3 and more than 1000 nM for the SRIF-2 subtypes, sst1 and sst4 receptors. It is used clinically in the management of acromegaly and symptoms caused by neuroendocrine tumors, and in recent studies can also inhibit tumor growth and has shown activity against non-endocrine tumors.

InChI:InChI=1/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)

Upstream product

• 64-19-7 acetic acid 
• 631-61-8 ammonium acetate 
• 1026080-86-3 H-D-β-Nal-Cys-(Acm)-Tyr-D-Trp-Lys-Val-Cys(Acm)-Thr-NH₂ 
• 108736-35-2 lanreotide 

Relevant articles and documents

SUBSTANTIALLY PURE LANREOTIDE OR ITS SALT and PROCESS THEREOF

The present invention provides substantially pure Lanreotide or its salt and preparation thereof. In another aspect present invention provides a method of preparing Lanreotide dmg product which involves measuring D-Allo-Threonine Lanreotide impurity content in the Lanreotide or its salt. The present invention also provides a method of assaying purity of a sample of Lanreotide or its salt or a pharmaceutical dosage form comprising Lanreotide or its salt.

PROCESS FOR PREPARATION OF LANREOTIDE ACETATE

The invention relates to an improved method for the solution phase synthesis of Lanreotide acetate (1) comprising coupling of two suitably protected tetrapeptide fragments wherein the threonine hydroxyl is protected, to give an octapeptide, which on deprotection, oxidation, followed by treatment with acetic acid provides Lanreotide acetate (1) having desired purity.

PROCESS FOR LANREOTIDE ACETATE PREPARATION

The invention relates to an improved method for 4+4 solution phase synthesis of Lanreotide acetate (1) comprising coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid to provide Lanreotide acetate (1) having desired purity.

PROCESS FOR PREPARATION OF LANREOTIDE ACETATE

Disclosed herein is an improved 4+4 solution phase synthesis of Lanreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid provides Lanreotide acetate having desired purify.

PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS

A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and aceti

Octapeptide compounds derived from somatostatin and the therapeutic use thereof

The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.

Counterion exchange process for peptides

The invention encompasses a process for purifying a peptide comprising loading a peptide onto a RP-HPLC column; washing the column with an aqueous solution of a pharmaceutically acceptable counterion salt; and eluting the peptide from the column with a solvent mixture of a organic solvent and an acid of the pharmaceutically acceptable counterion, wherein the aqueous solution has a pH of at least about 6.